Combination Chemotherapy with 5-Fluorouracil and Heptaplatin as First-line Treatment in Patients with Advanced Gastric Cancer.
10.3346/jkms.2004.19.3.369
- Author:
Young Joo MIN
1
;
Sung Jo BANG
;
Jung Woo SHIN
;
Do Ha KIM
;
Jae Hoo PARK
;
Gyu Yeol KIM
;
Byung Kyun KO
;
Dae Hwa CHOI
;
Hong Rae CHO
Author Information
1. Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
- Publication Type:Original Article
- Keywords:
Drug Therapy;
Fluorouracil;
Stomach Neoplasms;
Heptaplatin;
Platinum Compounds
- MeSH:
Adult;
Aged;
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use;
Disease-Free Survival;
Female;
Fluorouracil/*administration & dosage;
Follow-Up Studies;
Human;
Male;
Malonates/*administration & dosage;
Middle Aged;
Organoplatinum Compounds/*administration & dosage;
Stomach Neoplasms/*drug therapy;
Time Factors;
Treatment Outcome
- From:Journal of Korean Medical Science
2004;19(3):369-373
- CountryRepublic of Korea
- Language:English
-
Abstract:
Heptaplatin is a recently developed platinum derivative. This agent has been reported to have a response rate of 17% as a single agent, and tolerable toxicity in the treatment of advanced gastric cancer. The aim of this study was to evaluate the efficacy and toxicity of a combination of 5-fluorouracil (5-FU) and heptaplatin in patients with advanced gastric cancer. Forty-seven chemotherapy-naive patients with advanced or recurred gastric cancer were recruited. 5-FU was administered over 120 hr by continuous intravenous infusion from day 1 to 5, at a daily dose of 1,000 mg/m2 and heptaplatin was administered over 1 hr by intravenous infusion on day 1 at 400 mg/m2, and this cycle was repeated every 4 weeks. The response rate was 21%, median progression-free survival was 1.9 months (95% CI, 1.6 to 2.2 months). Median overall survival was 6.2 months (95% CI, 4 to 8.4 months) and the 1-yr survival rate was 29% for all patients. The most frequent toxicity was proteinuria. Toxicities were generally mild and reversible. This study demonstrates that the combination of 5-FU/heptaplatin combination is less active but tolerated in patients with advance gastric cancer.
